Cellanyx Publishes Clinical Proof-of-Concept Study of First-in-Class Biomarker Test to Determine Prostate Cancer Risk

Cellanyx Publishes Clinical Proof-of-Concept Study of First-in-Class Biomarker Test to Determine Prostate Cancer Risk

Source: 
CP Wire
snippet: 

Cellanyx and clinical collaborators today reported results of a prostate cancer clinical study demonstrating the ability of the company’s live tumor cell phenotypic biomarker test to identify patients with low and intermediate grade prostate cancer at risk of aggressive disease.